Patients Are Asking: Getting the Most Out of Blood Glucose Meters

May 31, 2008

Keeping glucose levels under control can help people with diabetes feel better and also lower the risk of blindness, kidney disease, and nerve damage. Very high or very low blood sugar can have serious consequences. Although blood glucose meter...

Written by Food and Drug Adminstration (FDA): Patient Safety News · Filed Under FDA: News/Recalls

Recalls and Safety Alerts: Avoid Using ReadyMED Infusion Pumps with Cubicin

May 31, 2008

In an April 4, 2008 letter, Cubist Pharmaceuticals advised healthcare professionals not to use the drug Cubicin with ReadyMED elastomeric infusion pumps manufactured by Cardinal Health. Cubicin (daptomycin for injection) is an antibiotic used to tre...

Written by Food and Drug Adminstration (FDA): Patient Safety News · Filed Under FDA: News/Recalls

Recalls and Safety Alerts: Neupro Patches Recalled

May 31, 2008

Schwarz Pharma recalled Neupro (rotigotine) transdermal patches at the end of April 2008. These patches are used to treat early stage Parkinson's disease. The problem is that rotigotine, the active ingredient, may crystallize in the patch. If th...

Written by Food and Drug Adminstration (FDA): Patient Safety News · Filed Under FDA: News/Recalls

Recalls and Safety Alerts: FDA Studying Potential Safety Issues with Several Drugs

May 31, 2008

FDA has informed the health care community about ongoing safety reviews of several drugs. FDA is doing this as part of its commitment to inform health care professionals and the public about its ongoing drug safety reviews. Because this information...

Written by Food and Drug Adminstration (FDA): Patient Safety News · Filed Under FDA: News/Recalls

Recalls and Safety Alerts: Inflammatory Masses with Synchromed and IsoMed Implantable Infusion Pumps

May 31, 2008

On January 16, 2008, Medtronic notified healthcare professionals about an increased rate of inflammatory masses in patients receiving intrathecal drugs through the company's Synchromed EL, Synchromed II and IsoMed implantable infusion pump systems. ...

Written by Food and Drug Adminstration (FDA): Patient Safety News · Filed Under FDA: News/Recalls

ASCO: Bevacizumab (Avastin) Alone Shows Edge in Recurrent Glioblastoma

May 30, 2008

CHICAGO -- For refractory glioblastoma, second-line bevacizumab (Avastin) as monotherapy has been associated with a 43% response rate and a progression-free edge, albeit nonsignificant, over the agent plus irinotecan (Camptosar).